Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00136474 · ClinicalTrials.gov registry record · Phase 2
Amifostine for Head and Neck Irradiation in Lymphoma
A Phase 2 study of Lymphoma and Non-Hodgkin's Lymphoma, sponsored by Dana-Farber Cancer Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 75
- Enrollment target
- 2
- Study locations
NCT00136474 is a Phase 2 study of Lymphoma and Non-Hodgkin's Lymphoma that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 75 participants, below the 483-participant average among 299 other Lymphoma trials with a reported enrollment target (84% lower). The trial reports 2 study locations across 1 state.
The verdict
NCT00136474, a Phase 2 study of Lymphoma and Non-Hodgkin's Lymphoma, has completed, sponsored by Dana-Farber Cancer Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 75 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this study is determine the effects (good and bad) amifostine has on radiation-induced side effects of lymphoma treatment.
Conditions Studied
Interventions
- RADIATION Radiation Therapy
- DRUG Amifostine
Study Locations (2)
Massachusetts
- Beth Israel Deaconess Medical Center - Boston
- Dana-Farber Cancer Institute - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 75 participants |
| Start Date | 2003-05 |
| Est. Completion | 2009-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00136474
The ClinicalTrials.gov registry entry for NCT00136474 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 75 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 483-participant average among 299 other Lymphoma trials with a reported enrollment target (84% lower). The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Lymphoma appearing as the primary indexed condition, and to 2 interventions - of which Radiation Therapy is the first listed.
NCT00136474 reports 2 study locations spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT00136474 about?
NCT00136474 is a clinical study titled "Amifostine for Head and Neck Irradiation in Lymphoma". The purpose of this study is determine the effects (good and bad) amifostine has on radiation-induced side effects of lymphoma treatment.
What is the current status of trial NCT00136474?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 75 participants. The study started on 2003-05. Estimated completion is 2009-03.
What conditions does trial NCT00136474 study?
This clinical trial studies the following conditions: Lymphoma, Non-Hodgkin's Lymphoma, Hodgkin's Disease.
What interventions are being tested in trial NCT00136474?
The interventions under investigation include: Radiation Therapy (RADIATION), Amifostine (DRUG).
Who is sponsoring clinical trial NCT00136474?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00136474 being conducted?
This trial has 2 study locations across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Epcoritamab in Patients With Follicular Lymphoma Not Accomplishing a CR With Upfront Chemoimmunotherapy
RECRUITING · Phase 2
-
A Phase II Study of Loncastuximab Tesirine as Consolidation Strategy in Patients With LBCL in PR After CAR T-cell Therapy
RECRUITING · Phase 2
-
Odronextamab in Low Tumor Volume Advanced FL
RECRUITING · Phase 2
-
A Study of Mosunetuzumab Alone or With Zanubrutinib in People With Follicular Lymphoma
RECRUITING · Phase 2
-
Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders
RECRUITING · Phase 2
-
Pilot Trial of Fecal Microbiota Transplantation for Lymphoma Patients Receiving Axicabtagene Ciloleucel Therapy.
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.